Advertisement
DXCM vs PODD
Which Stock Would AI Choose? DexCom (DXCM) vs. Insulet (PODD) Stock Comparison
Key Takeaways
- Both DXCM and PODD operate in the diabetes technology market, but their recent trajectories have diverged sharply.
- DXCM delivered a beat-and-raise quarter, expanding margins and raising its 2026 outlook, while PODD beat on earnings but guided 2027 growth below its prior framework.
- Tickeron AI Verdict: The AI currently favors DXCM, citing stronger trend consistency, positive catalysts, and more stable relative positioning versus PODD.
- For more context on each name, explore DXCM Major News and DXCM Today's Price Move, as well as PODD Major News and PODD Today's Price Move.
- To see how AI is applying these signals in live trading, explore the Trending AI Robots section.
Introduction
DexCom (DXCM) and Insulet (PODD) are two of the most closely watched names in diabetes care technology, yet they compete in adjacent rather than identical niches. DexCom is the leading maker of continuous glucose monitoring (CGM) sensors, while Insulet produces the Omnipod tubeless insulin delivery system. Both address the large and growing type 2 diabetes opportunity and increasingly integrate with each other's devices. This stock comparison is most relevant to investors seeking exposure to medical technology growth, as well as traders tracking relative performance and momentum shifts in the healthcare device sector. Recent quarters have highlighted meaningful differences in market positioning between the two.
DXCM Overview and Recent Performance
DXCM designs and commercializes CGM systems used to manage diabetes and broader metabolic health. Recent weeks have been constructive for the stock, which has gained roughly 25% year-to-date and rebounded sharply after a difficult 2025. In its latest quarterly report, DexCom posted revenue of about $1.34 billion, up roughly 11% year over year, with U.S. sales growing around 14% and adjusted earnings per share (EPS) exceeding consensus. Gross margin expanded several hundred basis points on manufacturing efficiencies and the ramp of its G7 15 Day sensor.
Sentiment has been supported by the publication of the CONNECT trial in the New England Journal of Medicine, which strengthens the clinical case for CGM use among non-insulin type 2 patients and underpins a potential Medicare coverage expansion. Management raised its full-year revenue guidance and authorized an additional $1 billion buyback, reinforcing confidence in the growth trajectory.
PODD Overview and Recent Performance
PODD develops and manufactures the Omnipod platform, a tubeless, wearable insulin delivery system. The company recently reported a strong quarter, with revenue of about $842 million, up roughly 19% year over year, and adjusted EPS that meaningfully beat estimates. Insulet also narrowed its 2026 revenue growth outlook toward the upper end of its prior range and announced a $1 billion increase to its share repurchase authorization.
Despite these results, the stock has come under pressure, trading well below its 52-week high reached in late 2025. The main headwind was forward guidance: management indicated 2027 growth may come in modestly below its earlier mid-teens framework, citing tougher comparisons, product-launch timing, and expectations of ceding a few share points to new competitors. This cautious outlook has weighed on market positioning even as underlying profitability continues to improve.
Trending AI Robots
Tickeron maintains a large library of AI Trading Bots spanning thousands of tickers and a wide range of strategies, timeframes, and risk profiles. Because not every bot suits every market environment, Tickeron curates only the most relevant and highest-performing systems into its Trending AI Robots section. These selected bots reflect current market conditions and are backed by detailed performance statistics, helping traders evaluate how algorithmic strategies are positioning across momentum, swing, and longer-horizon approaches. With hundreds of bots available, the curated list offers a practical starting point for identifying which automated strategies are presently resonating. Traders and investors interested in applying these signals to names like DXCM and PODD can review the Trending AI Robots page for current rankings and metrics.
Head-to-Head Comparison
The clearest contrast is in recent momentum. DXCM has been climbing within a recovery trend, while PODD has pulled back significantly from its highs despite strong quarterly execution. On business model, DexCom benefits from a recurring, sensor-based revenue stream and a broader push into non-insulin type 2 patients, whereas Insulet's growth is concentrated in a single hardware platform that faces rising competition from new patch-pump entrants.
Growth drivers also differ. DexCom's catalysts include reimbursement expansion, the G7 15 Day rollout, and upcoming product launches. Insulet's catalysts center on Omnipod 5 adoption, international expansion, and a planned Omnipod 6 launch. On risk factors, DexCom faces pricing and formulary competition in CGM, while Insulet faces a more concentrated product risk and explicit expectations of share erosion. Sector exposure is similar—both are healthcare devices—but their market sentiment and valuation setups currently point in different directions.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor DXCM over PODD in the current environment. DexCom exhibits stronger trend consistency, supported by an earnings beat, raised guidance, expanding margins, and a high-profile clinical catalyst in the CONNECT study. Insulet's fundamentals remain solid, but its softer 2027 outlook and anticipated competitive share losses introduce greater uncertainty into its near-term trajectory. While both stocks carry risk, the AI's preference leans toward the name with steadier momentum and more clearly defined near-term catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a StrongBuy and PODD is a Hold.
DXCM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for DXCM turned positive on November 02, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Oscillator exited the oversold zone, 25 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DXCM as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 199 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
DXCM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.431) is normal, around the industry mean (4.142). P/E Ratio (30.779) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PODD in upward trend: price rose above 50-day moving average on October 16, 2026
PODD moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for PODD crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.
Following a +7.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where PODD advanced for three days, in 208 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 104 of 174 cases where PODD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for PODD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 16 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PODD as a result. In 57 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for PODD turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
PODD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. PODD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.145) is normal, around the industry mean (4.142). P/E Ratio (27.334) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.047) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.294) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DXCM | PODD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 27 | 37 | |
PRICE GROWTH RATING 1..100 | 44 | 56 | |
P/E GROWTH RATING 1..100 | 52 | 96 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PODD's Valuation (77) in the Medical Specialties industry is in the same range as DXCM (83). This means that PODD’s stock grew similarly to DXCM’s over the last 12 months.
PODD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as DXCM (100). This means that PODD’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is in the same range as PODD (37). This means that DXCM’s stock grew similarly to PODD’s over the last 12 months.
DXCM's Price Growth Rating (44) in the Medical Specialties industry is in the same range as PODD (56). This means that DXCM’s stock grew similarly to PODD’s over the last 12 months.
DXCM's P/E Growth Rating (52) in the Medical Specialties industry is somewhat better than the same rating for PODD (96). This means that DXCM’s stock grew somewhat faster than PODD’s over the last 12 months.
| DXCM | PODD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 72% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 69% |
| Advances ODDS (%) | 10 days ago 67% | 8 days ago 66% |
| Declines ODDS (%) | 6 days ago 74% | 6 days ago 71% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green while PODD’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- PODD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 6 TA indicator(s) are bullish while PODD’s TA Score has 5 bullish TA indicator(s).
- DXCM’s TA Score: 6 bullish, 4 bearish.
- PODD’s TA Score: 5 bullish, 5 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а -3.68% price change this week, while PODD (@Medical/Nursing Services) price change was -4.39% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
DXCM is expected to report earnings on Feb 11, 2027.
PODD is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
DXCM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
|---|---|---|---|---|
| DXCM | 100% | -1.42% | ||
| ISRG - DXCM | 46% Loosely correlated | -2.28% | ||
| ALGN - DXCM | 44% Loosely correlated | N/A | ||
| LIVN - DXCM | 42% Loosely correlated | -1.59% | ||
| PODD - DXCM | 41% Loosely correlated | -1.17% | ||
| NVST - DXCM | 40% Loosely correlated | -0.50% | ||
More | ||||
PODD and
Correlation & Price change
A.I.dvisor indicates that over the last year, PODD has been loosely correlated with ISRG. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PODD jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To PODD | 1D Price Change % | ||
|---|---|---|---|---|
| PODD | 100% | -1.17% | ||
| ISRG - PODD | 49% Loosely correlated | -2.28% | ||
| DXCM - PODD | 48% Loosely correlated | -1.42% | ||
| MDT - PODD | 44% Loosely correlated | -1.17% | ||
| SYK - PODD | 41% Loosely correlated | -0.44% | ||
| ATEC - PODD | 40% Loosely correlated | -5.15% | ||
More | ||||